Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:58 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Changing Agendas on Sleep, Treatment and Learning in Epilepsy
NCT04610879 · King's College London · PHASE4 · terminated · last registry update 2020-11-02 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Following the internal pilot, the study did not meet prespecified stop/go criteria for continuation.” | – | Registry record, King's College London |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SCN1A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-09-20Results posted on the registry: Johns Hopkins University, Placebo + Bupropion XL (NCT02111798)
- 2021-05-14Results posted on the registry: Vanderbilt University, (R)-propafenone + (S)-Propafenone (NCT02710669)
- 2021-03-17Phase 3 first posted: Milton S. Hershey Medical Center, Shampoo and saline + Saline and Listerine (NCT04802408)
- 2021-03-10Phase 3 first posted: LXO Ireland, Cocaine Hydrochloride Nasal Solution + Cocaine Hydrochloride Nasal Solution (NCT04792034)
- 2020-12-01Phase 3 first posted: David J. Kopsky, phenytoin cream (NCT04647877)
- 2020-10-26Results posted on the registry: Otsuka Pharmaceutical Development & Commercialization, Inc., AVP-786 + Placebo (NCT02534038)
- 2020-10-22Results posted on the registry: Yale University, Methylphenidate + Alpha Methyl Para Tyrosine (AMPT) (NCT02152670)
- 2020-09-16Results posted on the registry: Otsuka Pharmaceutical Development & Commercialization, Inc., AVP-786 + Placebo (NCT02477670)
- 2020-07-09Phase 3 first posted: Otsuka Pharmaceutical Development & Commercialization, Inc., AVP-786 + Placebo (NCT04464564)
- 2020-05-29Phase 3 first posted: Otsuka Pharmaceutical Development & Commercialization, Inc., AVP-786 + Placebo (NCT04408755)
- 2020-01-14Phase 3 first posted: Pancreatic Cancer Action Network, Gemcitabine combined with nab-paclitaxel + Dose -mFOLFIRINOX (NCT04229004)
- 2019-11-29Results posted on the registry: New York State Psychiatric Institute, Placebo + Intranasal Oxytocin (NCT02255357)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision